IRCT20141025019669N21招募中3 期
Assessment of the Ellagic acid supplementation effect on lipid profile, liver enzymes, oxidative stress status and inflammatory factors in patients with non-alcoholic fatty liver disease: double-blind randomized clinical trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •18-55 years old patient with non-alcoholic fatty liver,
- •confirmation of non-alcoholic fatty liver with liver ultrasound
- •Having a body mass index of less than 30
- •A consent signed by the patient.
排除标准
- •Pregnancy and lactation
- •Infectious disease, inflammatory disease, Cushing's syndrome, adrenal gland tumor, hypothyroidism, diabetes, and cancer.
- •Taking antioxidant supplements in the last three months
- •Taking medication in the last three months including glucocorticoids drugs, lipid-lowering drugs, and weight-loss drugs.
研究者
相似试验
已完成
3 期
Ellagic acid supplementation in women with the poly cystic ovarian syndromePolycystic ovarian syndrome.Polycystic ovarian syndromeE28.2IRCT20141025019669N12Qazvin University of Medical Sciences60
招募中
3 期
Ellagic acid supplementation effect in patients with Major DepressiveMajor depressive episode.Major depressive disorder, single episodeIRCT20141025019669N15Mazandaran University of Medical Sciences60
招募中
3 期
Ellagic acid supplementation effect in patients with type 2 diabetesIRCT20141025019669N13Qazvin University of Medical Sciences44
已完成
3 期
Ellagic acid supplementation in patient with irritabe bowel syndromeIrritable bowel syndrome.K58.0Irritable bowel syndrome with diarrheaIRCT20141025019669N11Qazvin University of Medical Sciences44
尚未招募
3 期
Ellagic acid in multiple sclerosisMultiple sclerosisIRCT20120415009472N22Iran University of Medical Sciences46